D.E. Shaw & Co
IOVA icon

D.E. Shaw & Co’s Iovance Biotherapeutics IOVA Stock Holding History

D.E. Shaw & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.1M Buy
8,016,353
+4,186,558
+109% +$13.4M 0.02% 943
2025
Q4 		$10.5M Buy
3,829,795
+3,753,586
+4,925% +$8.68M 0.01% 1712
2025
Q3 		$165K Buy
76,209
+20,738
+37% +$49K ﹤0.01% 4310
2025
Q2 		$95.4K Buy
55,471
+16,195
+41% +$40.3K ﹤0.01% 4133
2025
Q1 		$131K Buy
39,276
+8,464
+27% +$43.7K ﹤0.01% 3991
2024
Q4 		$228K Sell
30,812
-36,936
-55% -$342K ﹤0.01% 4024
2024
Q3 		$636K Sell
67,748
-588,082
-90% -$5.57M ﹤0.01% 3568
2024
Q2 		$5.26M Sell
655,830
-1,696,336
-72% -$18.2M ﹤0.01% 1798
2024
Q1 		$34.9M Buy
2,352,166
+2,137,032
+993% +$24.9M 0.03% 628
2023
Q4 		$1.75M Buy
215,134
+177,372
+470% +$928K ﹤0.01% 2773
2023
Q3 		$172K Sell
37,762
-820,994
-96% -$5.36M ﹤0.01% 3790
2023
Q2 		$6.05M Sell
858,756
-1,501,195
-64% -$10.7M 0.01% 1716
2023
Q1 		$14.4M Sell
2,359,951
-1,861,809
-44% -$12.8M 0.02% 1105
2022
Q4 		$27M Buy
4,221,760
+1,526,540
+57% +$11.9M 0.03% 730
2022
Q3 		$25.8M Buy
2,695,220
+617,689
+30% +$7.12M 0.03% 704
2022
Q2 		$22.9M Buy
2,077,531
+1,952,904
+1,567% +$25.6M 0.03% 781
2022
Q1 		$2.08M Buy
124,627
+52,590
+73% +$813K ﹤0.01% 3257
2021
Q4 		$1.38M Buy
72,037
+62,523
+657% +$1.38M ﹤0.01% 3674
2021
Q3 		$235K Sell
9,514
-16,072
-63% -$379K ﹤0.01% 4492
2021
Q2 		$666K Sell
25,586
-212,183
-89% -$5.52M ﹤0.01% 3863
2021
Q1 		$7.53M Buy
237,769
+108,988
+85% +$4.52M 0.01% 1561
2020
Q4 		$5.98M Buy
128,781
+82,391
+178% +$3.27M 0.01% 1736
2020
Q3 		$1.53M Buy
+46,390
New +$1.42M ﹤0.01% 2572
2020
Q2 		– Sell
-26,715
Closed -$878K – 4106
2020
Q1 		$800K Buy
26,715
+4,526
+20% +$120K ﹤0.01% 2912
2019
Q4 		$614K Buy
+22,189
New +$505K ﹤0.01% 3283
2018
Q4 		– Sell
-22,754
Closed -$256K – 3871
2018
Q3 		$256K Buy
+22,754
New +$323K ﹤0.01% 3429
2017
Q1 		– Sell
-14,778
Closed -$103K – 3437
2016
Q4 		$103K Buy
+14,778
New +$102K ﹤0.01% 3344
2016
Q2 		– Sell
-17,176
Closed -$87K – 3417
2016
Q1 		$87K Buy
17,176
+3,282
+24% +$18K ﹤0.01% 3293
2015
Q4 		$107K Sell
13,894
-3,854
-22% -$26.7K ﹤0.01% 3666
2015
Q3 		$102K Sell
17,748
-6,159
-26% -$48K ﹤0.01% 3608
2015
Q2 		$219K Buy
+23,907
New +$267K ﹤0.01% 3548

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

D.E. Shaw & Co's IOVA Position: Q1 2026 in Review

D.E. Shaw & Co increased its Iovance Biotherapeutics (IOVA) stake by 109% in Q1 2026, buying an estimated $13.4M and bringing the position to 8,016,353 shares worth $28.1M. The position accounts for 0.02% of the portfolio, ranked #943.

D.E. Shaw & Co first reported a position in IOVA in Q2 2015 and has held it in 31 quarters since. The position peaked at $34.9M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • D.E. Shaw & Co held 8,016,353 shares of Iovance Biotherapeutics worth $28.1M as of Q1 2026.
  • D.E. Shaw & Co bought 4,186,558 Iovance Biotherapeutics shares in Q1 2026, an estimated $13.4M.
  • Iovance Biotherapeutics made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #943 holding.
  • D.E. Shaw & Co first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 31 quarters since.
  • D.E. Shaw & Co's Iovance Biotherapeutics position peaked at $34.9M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.